...
首页> 外文期刊>Infectious Diseases and Therapy >Activated Protein C has No Effect on Pulmonary Capillary Endothelial Function in Septic Patients with Acute Respiratory Distress Syndrome: Association of Endothelial Dysfunction with Mortality
【24h】

Activated Protein C has No Effect on Pulmonary Capillary Endothelial Function in Septic Patients with Acute Respiratory Distress Syndrome: Association of Endothelial Dysfunction with Mortality

机译:活化蛋白C对感染性急性呼吸窘迫综合征患者的肺毛细血管内皮功能没有影响:内皮功能障碍与死亡率的关联。

获取原文

摘要

IntroductionPulmonary capillary endothelium-bound (PCEB) angiotensin-converting enzyme (ACE) activity is a direct and quantifiable index of pulmonary endothelial function that decreases early in acute respiratory distress syndrome (ARDS) and correlates with its severity. Endothelial dysfunction is a major pathophysiology that underlies sepsis-related ARDS. Recombinant human activated protein C (rhAPC), now withdrawn from the market, has been used in the recent past as an endothelial-protective treatment in patients with septic organ dysfunction. MethodsWe investigated the effect of rhAPC on pulmonary endothelial function in 19 septic patients suffering from ARDS. Applying indicator-dilution type techniques, we measured single-pass transpulmonary percent metabolism (% M ) and hydrolysis ( v ) of the synthetic, biologically inactive, and highly specific for ACE substrate, 3H-benzoyl-Phe-Ala-Pro (BPAP), under first-order reaction conditions, and calculated lung functional capillary surface area before and after treatment with rhAPC. ResultsPulmonary endothelium ACE activity was severely impaired in septic patients with ARDS, and was not affected by rhAPC treatment. Additionally, poor outcome was related to a more profound decrease in PCEB-ACE activity. Angiotensin-converting enzyme–substrate utilization was statistically significantly lower in non-survivors as compared to survivors, with no changes over time within each group: BPAP % M : 32.7?±?3.4% at baseline to 25.6?±?2.9% at day 7 in survivors versus 20.8?±?2.8 to 15.5?±?5%, respectively, in non-survivors ( p =?0.044), while hydrolysis ( v ): 0.41?±?0.06 at baseline to 0.30?±?0.04 at day 7 in survivors compared to 0.24?±?0.04 to 0.18?±?0.06, respectively, in non-survivors ( p =?0.049). ConclusionrhAPC administration in septic patients with ARDS did not improve PCEB-ACE activity indices. However, these indices might be useful in the early recognition of septic patients with ARDS at high risk of mortality.
机译:引言肺毛细血管内皮结合(PCEB)血管紧张素转换酶(ACE)活性是肺内皮功能的直接和可量化的指标,在​​急性呼吸窘迫综合征(ARDS)早期会降低,并与其严重程度相关。内皮功能障碍是脓毒症相关ARDS的主要病理生理学。重组人活化蛋白C(rhAPC),现已从市场上撤出,最近已被用作脓毒性器官功能障碍患者的内皮保护治疗。方法我们调查了rhAPC对19名ARDS脓毒症患者肺内皮功能的影响。我们采用指示剂稀释型技术,测量了合成的,对生物无活性且对ACE底物 3 H-苯甲酰基-高度特异的合成的单程跨肺代谢百分比(%M)和水解(v)。在一级反应条件下,用Phe-Ala-Pro(BPAP)计算了rhAPC治疗前后的肺功能毛细血管表面积。结果败血性ARDS患者的肺内皮ACE活性受到严重损害,不受rhAPC治疗的影响。此外,不良的结局与PCEB-ACE活性的更严重降低有关。与非存活者相比,非存活者的血管紧张素转化酶-底物利用率在统计学上显着降低,每组中随时间的变化无变化:BPAP%M:基线时为32.7%±3.4%,当日为25.6%±2.9%幸存者中为7,而非幸存者分别为20.8?±?2.8至15.5?±5%(p =?0.044),而水解度(v):基线为0.41?±?0.06到0.30?±?0.04。幸存者的第7天与非幸存者分别为0.24±0.04至0.18±0.06(p =±0.049)。结论在败血症的ARDS患者中给予rhAPC不能改善PCEB-ACE活性指数。然而,这些指标可能有助于早期识别败血症的高危死亡ARDS患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号